UGenome AI and Jeeva Clinical Trials Partner to Power Faster, Smarter Precision‑Medicine Studies

Source: UGenome AI

Integrated genomics pre‑screening + modular CTMS aims to cut screen‑failures and accelerate first‑patient‑in for biomarker‑driven trials

for immediate release

Tucson, AZ & Manassas, VA — August 21, 2025 — UGenome AI, a pioneer in personalized‑genomics software, and Jeeva Clinical Trials, the unified‑or‑modular CTMS provider for decentralized and hybrid studies, today announced a strategic partnership to help sponsors and CROs run faster, more cost‑effective precision‑medicine trials.

The collaboration connects UGenome AI’s genomic pre‑screening and pharmacogenomics decision tools with Jeeva’s CTMS stack—including multilingual eConsent, ePRO/eCOA, EDC, TeleVisits, and TrialMagnet™ AI analytics—so sponsors can identify eligible patients sooner, lower screen‑failure rates, and move from feasibility to first‑patient‑first-visit in weeks, not months.

“Making genomic medicine personal and accessible starts with finding the right patients at the right time,” said Zachary Brooks, PhD, Founder & CEO of UGenome AI. “By integrating our genomic pre‑screening and PGx insights with Jeeva’s modern CTMS, we can route high‑probability matches directly to investigators, streamlining enrollment for oncology, rare‑disease, and women’s‑health studies.”

Why this partnership matters now

Precision‑medicine and cell‑/gene‑therapy programs face high screen‑failure rates driven by biomarker rarity, tumor heterogeneity, and complex combination regimens—pressures that inflate timelines and cost (Bae et al., 2024). Literature continues to highlight challenges for targeted oncology, including heterogeneity and biomarker selection, combination‑therapy complexity, and CGT safety considerations that stretch trial design and operational budgets (Lopez & Banerji, 2016 & Mayo Clinic, 2024).

The UGenome–Jeeva integration addresses these pain points end‑to‑end:

• Genome‑first pre‑screening: UGenome AI flags candidate participants via variant calling and PGx logic; eligible matches are programmatically referred to study sites.
• Frictionless consent & enrollment: Jeeva’s 100+‑language eConsent and BYOD ePRO reduce lag from IRB/EC localization and patient onboarding.
• Unified data flow: Genomic eligibility, consent, ePRO, visit data, and endpoints live in a single CTMS, minimizing reconciliation and query cycles.
• Predictive operations: Jeeva’sTrialMagnet™ uses real‑time signals to forecast dropout risk and enrollment velocity, allowing teams to intervene early.

“Sponsors shouldn’t have to choose between scientific precision and operational speed,” said Harsha K. Rajasimha, PhD, Founder & CEO of Jeeva Clinical Trials. “UGenome AI brings genome‑first rigor; Jeeva brings a rapid, modular CTMS. Together, we’re eliminating the hand‑offs that slow targeted therapy trials and helping teams reach first‑patient‑in faster—while improving retention and data quality.”

What sponsors and CROs can expect

For emerging biopharma & medtech sponsors

• Faster startup with pre‑validated templates (oncology, rare‑disease, device/IVD) and integrated genomic eligibility checks.
• Lower screen‑failures by focusing outreach on biomarker‑matched patients before expensive site visits.
• Global readiness through built‑in multilingual consent, remote visits, and GDPR/21 CFR Part 11–aligned audit trails.

For niche CROs

• White‑label option to deploy the combined solution under the CRO’s brand—winning more bids without building internal tech.
• Shorter cycles & better margins from fewer manual reconciliations between genomics vendors, EDC, and spreadsheets.

Early results & availability

Pilot deployments have demonstrated material reductions in startup friction, with sponsors reporting shorter IRB/EC cycles for localized consent and meaningful decreases in screen‑failures when UGenome’s pre‑screening is used ahead of site referrals. The combined workflow is available immediately to new and existing customers of both companies. Joint implementation packages include 30‑day Fast‑Track onboarding, API enablement, and optional co‑marketing support.

• Organizations attending BIO‑Europe and ESMO this fall can schedule live demonstrations of the integrated solution.

About UGenome AI

UGenome AI is a startup biotech company focusing on developing genomics software. UGenome AI is advancing genomics analysis and helping patients receive personalized care, faster. Our products stem from our personalized reference genome and pharmacogenomics tools to help patients receive personalized treatments within weeks, not years. For more information, please visit www.ugenome.io.

About Jeeva Clinical Trials

Jeeva Clinical Trials provides a unified‑or‑modular, AI‑enabled CTMS that launches decentralized and hybrid studies in ≤4 weeks. The cloud‑agnostic platform brings eConsent, ePRO/eCOA, EDC, TeleVisits, inventory, and TrialMagnet™ analytics together under one login to help emerging biopharma and medtech sponsors run faster, more inclusive trials with lower total cost of ownership. Learn more at www.jeevatrials.ai.

Contacts

For UGenome AI Inquiries:

Zachary Brooks

zachbrooks@ugenome.io

For Jeeva Clinical Trials Inquires:

Media Relations

pr@jeevatrials.com

References

1. Bae, W.H., Maraka, S., & Daher, A. (2024). Challenges and advances in glioblastoma targeted therapy. Frontiers in Oncology. https://doi.org/10.3389/fonc.2024.1441460
2. Lopez, J.S., & Banerji, U. (2016). Combine and conquer: challenges for targeted therapy combinations in early‑phase trials. Nat Rev Clin Oncol, 14(1), 57–66. https://doi.org/10.1038/nrclinonc.2016.96
3. Mayo Clinic (2024). Gene Therapy—Risks and considerations. https://www.mayoclinic.org/tests-procedures/gene-therapy/about/pac-20384619